FGF18–FGFR2 signaling triggers the activation of c-Jun–YAP1 axis to promote carcinogenesis in a subgroup of gastric cancer patients and indicates translational potential

Jinglin Zhang1,2,3 · Chi Chun Wong2 · Kam Tong Leung4 · Feng Wu1 · Yuhang Zhou1,2,3 · Joanna H. M. Tong1,2,3 · Ronald C. K. Chan1 · Hui Li1,2,3 · Yifei Wang1,2,3 · Huan Yan1,2,3 · Liping Liu5 · William K. K. Wu6 · Michael W. Y. Chan2 · Alfred S. L. Cheng8 · Jun Yu2,9 · Nathalie Wong3,10 · Kwok Wai Lo1,3 · Ka Fai To1,2,3 · Wei Kang1,2,3

Abstract
Fibroblast growth factor receptor type 2 (FGFR2) has emerged as a key oncogenic factor that regulates gastric cancer (GC) progression, but the underlying mechanism of FGF–FGFR2 signaling pathway remains largely unknown. To identify the potential molecular mechanisms of the oncogenic FGFR2 in gastric carcinogenesis and convey a novel therapeutic strategy, we profiled the FGFR alterations and analyzed their clinical associations in TCGA and Hong Kong GC cohorts. We found that FGFR2 overexpression in GC cell lines and primary tumors predicted poor survival and was associated with advanced stages of GC. Functionally, growth abilities and cell cycle progression of GC were inhibited by inactivation of ERK–MAPK signal transduction after FGFR2 knockdown, while apoptosis was promoted. Meanwhile, the first-line anti-cancer drug sensitivity was enhanced. RNA-seq analysis further revealed that YAP1 signaling serves as a significant downstream modulator and mediates the oncogenic signaling of FGFR2. When stimulating FGFR2 by rhFGF18, we observed intensified F-actin, nuclear accumulation of YAP1, and overexpression of YAP1 targets, but these effects were attenuated by either FGFR2 depletion or AZD4547 administration. Additionally, the FGF18–FGFR2 signaling upregulated YAP1 expression through activating c-Jun, an effector of MAPK signaling. In our cohort, 28.94% of GC cases were characterized as FGFR2, c-Jun, and YAP1 co-positive and demonstrated worse clinical outcomes. Remarkably, we also found that co-targeting FGFR2 and YAP1 by AZD4547 and Verteporfin synergistically enhanced the antitumor effects in vitro and in vivo. In conclusion, we have identified the oncogenic FGF–FGFR2 regulates YAP1 signaling in GC. The findings also highlight the translational potential of FGFR2–c-Jun–YAP1 axis, which may serve as a prognostic biomarker and therapeutic target for GC.

Introduction
Gastric cancer (GC) is one of the most lethal malignancies globally and remains a prevalent malignancy in Eastern Asia areas, including Hong Kong [1]. Recently, the number of GC cases is increasing among the younger population [2–4].

Regarding the histological characteristics, over 90% of the cases are adenocarcinomas. By Lauran’s classification, GC can be subgrouped as the intestinal type and diffuse type [5]. A more comprehensive molecular classification has been proposed by The Cancer Genome Atlas (TCGA) consortium, consisting of four major molecular subtypes: microsatellite instability, Epstein-Barr virus-associated GC, chromosomal instability, and genomically stable (GS) [6].

GC is a heterogeneous disease with multiple pathogenic mechanisms such as aberrant crosstalk of signaling pathways [7–9]. As we previously reported, a prominent fibroblast growth factor (FGF) family member FGF18 is highly upregulated in GC. We found FGF18 stimulation activates several signaling pathways in GC, such as ERK–MAPK and TGFβ–SMAD2/3 [10]. The FGF receptors (FGFRs) are known as transmembrane tyrosine kinases. Activation of
FGFR initiates the downstream cascades by binding with certain FGFs [11]. Aberrant activation of FGFRs contributes to tumorigenesis by stimulating cell proliferation and migration [12, 13]. In cancer cells, genetic and epigenetic modifications of FGFR2 lead to overexpression, fusion protein, and increased ligand-binding affinity. Meanwhile, somatic mutations on the functional domains of FGFRs can trigger constitutive self-activation [12, 14, 15]. Preclinical and experimental work has validated the tumor-promoting role of FGFR2 in tumorigenesis and metastasis of GC [16–19]. FGFR2 gene amplification rates about 5–10% in GC cases [20]. Besides, alternative splicing produced FGFR2 isoforms, FGFR2b and FGFR2c, harbor exclusive binding affinities to FGFRs. FGFR2b overexpression is known as an accurate indicator for GC patients who are more sensitive to FGFR2 inhibitors [21].

Targeting aberrant activation of FGFR2 represents a novel therapeutic strategy in GC. Specific antibodies or small molecules targeting the FGFR–FGFR have been developed and are undergoing clinical trials [22]. However, tyrosine kinase inhibitors are effective only in a small portion of GC patients. High intra-tumor heterogeneity is one of the causes of drug resistance [23], while other resistant mechanisms remain poorly understood. In several selective pan-FGFR inhibitors, AZD4547 demonstrates the most promising effect in a subgroup of patients with FGFR2 amplification [24]. Nevertheless, FGFR-targeted treatments are still under evaluation in Phase I/II clinical trials.

In this study, we aim to elucidate the molecular mechanisms and evaluate the translational potential of FGFR–FGFR signaling cascade as a biomarker and therapeutic target in GC.

Results

FGFR2 is overexpressed and predicts poor survival of GC patients

By the cBioportal analysis, TCGA dataset was used to demonstrate the genetic and epigenetic alterations of FGFRs in primary GC cases. Thirty-six percent of the cases have at least one alteration in FGFR members (Fig. 1a), including copy number changes, somatic mutations, and mRNA upregulation. Genetic or mRNA change in FGFR1–4 accounts for 12%, 13%, 10%, and 9% of GC cases, respectively, and FGFR2 expression demonstrates a positive correlation with its copy number gain/ gene amplification, suggesting that copy number aberration partially contributes to overexpression of FGFR2 (p < 0.001, Fig. 1b). By Kaplan–Meier plotter analysis (based on multiple GSE cohorts: GSE14210, GSE15459, GSE22377, GSE29272, GSE51105, and GSE62254), high expression of FGFR2 was associated with poor overall survival and first progression survival (Fig. 1c). Moreover, the copy number aberrations of FGFR2 were assessed by using FGFR2 probes for CISH analysis in 264 samples of our in-house Hong Kong cohort. Eighty-seven percent of cases were counted to be diploid, 6% possessed copy number gain, and the rest 7% of cases harbored gene amplification (Fig. 1d). At the protein level, FGFR2 predominantly localized in the cell cytoplasm and membrane both in intestinal and diffuse type GC by IHC analysis (left panel, Fig. 1e) and can be categorized into low and high expression groups (total 264 cases were counted for scoring) according to our previous method [25]. Significantly, overexpression of FGFR2 indicated a poor disease-specific survival of patients (right panel, Fig. 1e) and correlated with several clinicopathologic parameters, implying aberrant FGFR2 activation might contribute to advanced stage of GC. By univariate Cox regression analysis, older age, diffuse histological type, high grade, advanced stage, lymph node metastasis, and FGFR2 overexpression were correlated with unfavorable outcomes (Supplementary Table S1). By multivariate analysis, only older age and advanced stage were independently associated with poor prognosis (Supplementary Table S2). Further, the mRNA expression of four FGFRs was evaluated in eleven GC cell lines. FGFR2 showed dramatic upregulation in most of these GC cell lines compared with the normal gastric cell line GES-1, while other FGFR members did not demonstrate such significant upregulation (Fig. 1f). Upregulating protein level of FGFR2 was consistent with its mRNA upregulation in most of the GC cell lines, especially in KATO III, MGC-803, AGS, and MKN28 cells (Fig. 1g).

FGFR2 knockdown exerts an antineoplastic effect in GC

To further elucidate the functional role of FGFR2, siRNA-mediated knockdown was performed. Two independent commercial siRNAs targeting FGFR2 and one control siScramble were transfected into several GC cell lines (AGS, MKN28, MGC-803) with high level of FGFR2 accordingly. Knockdown efficiency was firstly confirmed by qRT-PCR (Fig. 2a). FGFR2 knockdown induced significant inhibition of cell proliferation, monolayer colony formation ability, and cell invasion ability in AGS, MKN28, and MGC-803 (Fig. 2b–d). To further investigate the antitumor effect of FGFR2 silencing, we employed flow cytometry to analyze apoptosis and cell cycle distribution. As indicated, the proportion of both early and late stage apoptotic cells were significantly increased in siFGFR2 transfectants (Fig. 2e). As to cell cycle distribution, G1 phase population was increased in siFGFR2 transfectants (Fig. 2f). Looking at the alteration of apoptotic and cell cycle markers, cleaved PARP was increased, cell cycle related proteins cyclin D1 and p-Rb were inactivated, and p21 and p27 expression were induced in siFGFR2 transfectants compared with
siScramble control. Moreover, FGFR2 depletion inactivated the ERK–MAPK signaling (Fig. 2g). To assess whether FGFR2 related to first-line anti-cancer drug resistance in GC, cells with either siFGFR2 or siScramble control were treated with escalating concentrations of fluorouracil (5-FU) and cell viability was detected subsequently. IC$_{50}$ was significantly decreased by the transfection of both FGFR2 siRNAs compared with siScramble control (Fig. 2h). Together, we observed that knockdown of FGFR2 not only triggered an antineoplastic effect by inducing apoptosis and inhibiting cell cycle progression, but also enhancing the 5-FU sensitivity in GC cells.
YAP1 is a prominent downstream of FGF–FGFR2 signaling

We previously identified FGFR18 as a potent oncogenic driver in gastric tumorigenesis [10]. As FGFR2 highly expressed in GC cells, we hypothesized that FGFR2 is the major responding receptor for FGF18 in GC. To investigate the functional downstream of FGFR2, we performed RNA-seq on MGC-803 cells, which either treated with recombinant human FGF18 (rhFGF18) or transfected with a siFGFR2. In rhFGF18-stimulated cells, Gene Ontology (GO) analysis indicated that the deregulated genes were mainly enriched in biological processes including serine/threonine kinase activity, protein phosphorylation, and GTPase activity (Fig. 3a and Supplementary Table S3). Among the top-ranking signaling pathways, we observed that multiple genes related to Hippo–YAP1 signaling were highly altered. Expression levels of these genes were further validated by qRT-PCR. YAP1, MYC, CTGF, and CCND1 were upregulated, while TP73 and AMOT were decreased (Fig. 3b and Supplementary Table S3). Meanwhile, FGFR2 knockdown was highly associated with the signal transduction of p53, apoptotic signaling pathway, and inactivation of MAPK activity (Fig. 3c and Supplementary Table S3). Most genes validated for rhFGF18 stimulation were also highly altered by FGFR2 knockdown. The YAP1–TEAD4 complex and its downstream MYC, CCND1, and CCND3 were downregulated, whereas the apoptosis-related genes, TP73 and PPP2R2B were upregulated (Fig. 3d and Supplementary Table S3). YAP1 is found as a prominent downstream factor of the FGF18–FGFR2 signaling. To elucidate the potential role of YAP1 in this signaling, rhFGF18 was used to simulate the FBS-deprived GC cells for different time points (0–8 h). At the mRNA level, YAP1 was upregulated in GC cell lines after 2 and 4 h of stimulation (Fig. 3e). At the protein level, YAP1, CTGF, and a mesenchymal marker N-cadherin were elevated after rhFGF18 stimulation in a time-dependent manner (Fig. 3f). We also employed immunofluorescence staining to confirm the upregulation of YAP1. Nuclear YAP1, the functional oncogenic form of YAP1, was remarkably enriched in nuclei after 4 and 8 h of stimulation (Fig. 3g). We further identified whether FGFR2 knockdown abolishes the activation effect of rhFGF18. With FGFR2 depletion, YAP1, CTGF, c-Myc, and Bcl2 were no longer responding to the rhFGF18 stimulation in AGS, MKN28, and MGC-803 cells, indicating that the FGFR2 activated YAP1 signaling is suppressed (Fig. 3h). To confirm whether the Hippo signaling pathway has crosstalk with the FGF18–FGFR2 signaling, the upstream regulators of YAP1 were examined. Phospho-LATS1/2 (S909/S872), LATS1, LATS2, and phospho-YAP1 (S127) did not show significant changes in the rhFGF18-stimulated cells, hinting that rhFGF18 activated YAP1 expression is Hippo-independent (Fig. 3i). Previous evidence indicated that the nuclear activation of YAP1 is intermediated by the dynamics of F-actin cytoskeleton [26]. Apart from the YAP1 translocation, rhFGF18 also altered the arrangement of F-actin cytoskeleton. siFGFR2 transfection abolished YAP1 nuclear translocation and ameliorated the F-actin cytoskeleton to the naïve status even with rhFGF18 stimulation (Fig. 3j).

AZD4547 suppresses YAP1 signaling through inhibiting FGFR2

To explore whether inhibition of FGFR2 affects the potential downstream YAP1 signaling in GC, AGS and MGC-803 were treated with a pan-FGFR inhibitor AZD4547, which is highly sensitive to FGFR2. According to the IC50, MGC-803 cells are more sensitive to AZD4547 than AGS (Fig. 4a). The monoclonal colony formation ability of MGC-803 cells was increased by rhFGF18 (50 ng/ml), while AZD4547 (5 μM) abrogated the effect (Fig. 4b). Treatment of rhFGF18 increased the level of phosphorylated FGFR (p-FGFR), MEK (p-MEK), and ERK (p-ERK), but additional AZD4547 abolished the FGFR and MEK–ERK activation (Fig. 4c). It not only indicated that rhFGF18 activates FGFR2, but also confirmed that the MAPK signaling is responsible for signal transduction of the FGF18–FGFR2 axis. Furthermore, inhibition of FGFR2 by AZD4547 altered the cytoskeleton structure in MGC-803 cells. F-actin associates with cell migration, and α-Tubulin is an indispensable factor for cell division. With FGF18 stimulation, both F-actin and α-Tubulin were intensified. While in the cells treated with AZD4547, F-actin and α-Tubulin were disrupted. The stimulatory effect of rhFGF18 did not fully restore the...
Fig. 2 Depletion of FGFR2 in GC cells exhibits an antitumor effect. a The mRNA expression of FGFR2 in AGS, MKN28, and MGC-803 cells after transfection with siFGFR2s (***p < 0.001). b Knockdown of FGFR2 suppressed cell proliferation of the cancer cells (**p < 0.01). c siRNA-mediated knockdown of FGFR2 inhibited monolayer colony formation ability of GC cells (*p < 0.05; **p < 0.001). d Knocking down FGFR2 decreased cell invasion ability (**p < 0.001) (Scale bar, 50 μm). e siFGFR2 induced late and early apoptosis which was manifested by flow cytometry analysis (***p < 0.001). f Cell cycle distribution of siFGFR2 transfectants and siScramble control group by flow cytometry analysis. g Western blot analysis of MARK signaling, cell cycle regulators, and apoptosis biomarker cleaved PARP after FGFR2 knockdown. h The antitumor efficiency of 5-FU after FGFR2 knockdown in AGS and MKN28 was demonstrated by IC50. All experiments were performed in triplicate.
effects caused by AZD4547 (Fig. 4d). Under treatment of AZD4547, the YAP1 downstream effectors, CTGF and c-Myc, were suppressed in a dose-dependent manner (Fig. 4e). CTGF and c-Myc were only partly rescued by rhFGF18 stimulation in GC cells, compared with those by AZD4547 treatment only (Fig. 4f). It indicated that FGF18–FGFR2 signaling contributes
Together, targeting FGFR2 by small molecules inhibited YAP1 cleaved-caspase-3 was increased (Supplementary Fig. S1D). Expression of YAP1 and Ki-67 were also decreased, but in KATO III-derived xenografts after AZD4547 treatment (Supplementary Fig. S1C). Additionally, expression of FGFR2 was reduced in all three GC cell lines transfected with siFGFR2s to yield a knockdown effect. With serum deprivation and a followed FBS stimulation, p-FGFR and p-c-Jun were reduced in MGC-803 cells.

FGF18–FGFR2 regulate YAP1 expression through c-Jun activation

Although YAP1 is known as a proto-oncogene in multiple cancers, its transcriptional regulation remains largely unknown. To identify the mediator between FGFR2 and YAP1, we searched the JASPAR 2020 database [27] for core transcription factors (TFs) and noticed JUN is frequently shown among the high-ranked TFs enriched in the YAP1 promoter region (Supplementary Table S4). c-Jun has been well characterized as a downstream effector of the MAPK signaling pathway. We hypothesized that c-Jun is a potential TF underlying FGFR2-MAPK signaling and regulates YAP1 expression. GC cell lines were transfected with siFGFR2s to yield a knockdown effect. With serum deprivation and a followed FBS stimulation, p-FGFR and p-c-Jun were reduced in all three GC cell lines transfected with siFGFR2 (Fig. 5a). rhFGF18 stimulation activates p-FGFR and p-c-Jun. However, the stimulatory effect was eliminated in the siFGFR2 transfectants. It further implies the FGF18–FGFR2 activation promotes c-Jun phosphorylation (Fig. 5b). By TRANSFAC (version 8.3) prediction, two c-Jun binding sites were identified and selected within 2000 bp upstream from the transcription start site of YAP1 (Fig. 5c). The enrichment of c-Jun on the YAP1 promoter region was confirmed by ChIP-qPCR. When knocking down FGFR2, the enrichment of c-Jun was inhibited, suggesting that FGFR2 is required for the transcription regulation of c-Jun on YAP1 (Fig. 5d). siRNA-mediated JUN knockdown significantly decreased YAP1 mRNA expression. Consistently, the protein level of YAP1 together with its downstream factors, CTGF and c-Myc, were downregulated by siJUN (p < 0.001, Fig. 5e). Since YAP1 regulates multiple oncogenes during gastric carcinogenesis by cooperating with TEADs, the interaction status of YAP1/TEAD4 was examined by immunoprecipitation assay in MGC-803 cells. Knocking down either FGFR2 or JUN dissociated the YAP1/TEAD4 complex (Fig. 5f). The knockdown of JUN led to the suppression of cell proliferation (Fig. 5g) and monolayer colony formation in GC cell lines (Fig. 5h).

Further, ectopic overexpression of YAP1 in siJUN transfectants (Supplementary Fig. S1E) partly rescued the suppressed colony formation (Fig. 5i) and cell invasion abilities (p < 0.001, Fig. 5j). These results support that c-Jun mediated the regulation of FGF18–FGFR2 on YAP1 expression. To assess the therapeutic potential of targeting JUN and YAP1, a first-line chemo-drug 5-FU was employed to treat the siJUN, siYAP, or siScramble transfectants, respectively. IC_{50} was decreased in both siJUN and siYAP transfectants (Fig. 5k), indicating the JUN and YAP1 might be involved in the chemoresistance of GC.

Co-overexpression of FGFR2–c-Jun–YAP1 axis indicates poor outcomes

In the TCGA-GC cohort, genetic and epigenetic alterations of the FGF18–FGFR2–JUN–YAP1 axis were profiled by the cBioportal. Changes of each gene were mutually exclusive (p < 0.001), implying a single component change in this axis might drive gastric tumorigenesis (Fig. 6a). A positive correlation between FGFR2 and YAP1 expression was observed in GC cases. Herein, the diffuse type cases display a more stringent correlation (Fig. 6b). A positive correlation between YAP1 and JUN expression was also observed. The expression correlation is much stronger in the diffuse type GC samples (Fig. 6c). We, therefore, proposed that FGFR2–c-Jun–YAP1 was co-activated in a proportion of primary GC cases. In a Hong Kong cohort, tissue microarray samples of GC were stratified into two groups, the FGFR2/c-Jun/YAP1 co-activation group (28.94%) and
the inactivation group (71.06%). The representative cases were demonstrated by different resolutions (Fig. 6d). By IHC analysis, some cases showed co-overexpression of FGFR2, c-Jun, and YAP1, while some cases were negative for these three proteins. The membrane/cytoplasmic FGFR2, nuclear c-Jun, and nuclear YAP1 were co-counted for survival analysis. The FGFR2–c-Jun–YAP1 co-activation group (79 out of 273) was positively correlated with poor disease specific. We further analyzed the differential power of the subgrouping in intestinal and diffuse subtypes, respectively. In whatever type of GC, the co-positive group is significantly associated with an unfavorable outcome compared with other cases (Fig. 6e). The stratification conveys a promising therapeutic target to the precision intervention of GC.

Co-administration of small molecules for targeting the FGFR2–YAP1 axis

To evaluate the effect of targeting the FGFR2–YAP1 axis, small molecules targeting FGFR2 and YAP1 were employed individually or in combination. Verteporfin (VP) is a small molecule blocking the YAP1–TEAD complex. The dose-response of VP was tested in MGC-803 (Supplementary Fig. S1F). In vitro combinational effect was tested by monolayer colony formation assay. The MGC-803
cells were treated with either AZD4547 (5 µM) or VP (2 µM) alone, or in combination (cells were treated with 5 µM AZD4547 for 24 h and then added with 2 µM VP for another 24 h). In total, 0.1% DMSO in PBS treatment was used as vehicle control. The predicted value of the combined group was calculated by multiplying the relative
colony formation ability of the AZD4547 treated cells by that of VP treated cells. The effect was deemed synergistic when the observed value was less than the predicted value (Fig. 7a). In vivo synergistic effect was evaluated in xenograft formation models. Co-administration of MGC-803-derived xenografts with VP (a YAP1 inhibitor) and AZD4547 exerted a synergetic effect on tumor growth inhibition (Fig. 7b). IHC for FGFR2, YAP1, Ki-67, and cleaved PARP expression in these xenografts was performed and signals were captured under a microscope (Fig. 7c). The expression analysis manifested that the protein level of FGFR2, YAP1, and Ki-67 was further decreased by the combinational treatment of AZD4547 and VP, compared with the single treatment groups. While the expression of cleaved PARP was increased by the co-administration \((n=3, \text{ Fig. 7d})\). This demonstrates co-targeting FGFR2 and its downstream effector YAP1 might serve as a potential therapeutic strategy in GC.

In summary, we demonstrated the overexpression of FGFR2 in GC as well as its promoting role in gastric carcinogenesis. FGFR18–FGFR2 axis promotes gastric progression by activating ERK–MAPK signaling. c-Jun is confirmed as a TF of YAP1. Serving as a potential downstream effector of FGFR18–FGFR2, YAP1 transduces the oncogenic FGFR2 signaling into transcriptional events. F-actin cytoskeleton changes, which serves as a mechanotransduction mechanism for YAP1 nuclear translocation, is also regulated by FGFR18–FGFR2. Co-activation of the FGFR2–c-Jun–YAP1 pathway was revealed in a group of GC cases and predicts unfavorable clinical outcome. A combination blockade of FGFR2 and YAP1 may benefit more GC patients undergoing targeted therapy (Fig. 8).

**Discussion**

The oncogenic roles and clinical implications of FGFR–FGFR family members have been dissected in various types of cancer. The FGFR–FGFR signaling promotes cancer progression by the cross-talk with several canonical signaling pathways, contributing to the survival and metastasis of tumor cells [23, 28–30].

The therapeutic implication of FGFR2 in GC has been investigated for years. Co-occurrence of receptor tyrosine kinases and FGFR2 not only promotes GC progression but also leads to the acquisition of drug resistance. For instance, activation of epidermal growth factor receptor, human epidermal growth factor receptor 3, and MET induces drug resistance in GC cells with FGFR2 amplification [31]. On the other hand, signaling pathways such as ERK–MAPK [32], PI3K–Akt–mTOR [33], PLCγ–PKC [34], and JAK–STAT3 [35] are highlighted as canonical mechanisms involved in the oncogenic FGFR regulatory network. Although the copy number variation of FGFR2 is reported in GC, the detailed mechanism for its downstream signaling regulation is not unraveled. Identification of crucial downstream signaling of FGFR2 signaling in GC becomes imperative. In this study, we focused on deciphering molecular networks of FGFR2 and providing potential therapeutic strategies for GC. Among the four major FGFR members, FGFR2 shows the highest expression across multiple GC cell lines. The proportion of FGFR2 amplification cases in the Hong Kong cohort is relatively higher in diffuse type GC than it is in intestinal type GC, concordant with other reports [21, 36, 37]. Apart from gene amplification, there is a proportion of GC patients harboring FGFR2 overexpression. Our results indicated that FGFR2 mRNA abundance significantly correlates with poor clinical outcomes. A previous meta-analysis also highlighted the pathological and prognostic importance of FGFR2 protein overexpression in GC patients of multiple sources [38]. Thus, from both mRNA level and protein level, FGFR2 overexpression is supposed to be a promising biomarker for the prognosis of GC. As to the functional role, depletion of FGFR2 leads to suppression of tumor growth by inducing G1 phase cycle arrest and apoptosis. We confirmed the ERK–MAPK as the main downstream signaling pathway of FGFR2. By RNA-seq analysis, cells with FGFR18 stimulation or FGFR2 depletion revealed a subset of Hippo-YAP1 genes was dysregulated. YAP1, the key component of the Hippo-YAP1 pathway, was revealed as a potent downstream effector regulated by FGFR18–FGFR2 signaling. Previously, the oncogenic role of YAP1 has been well characterized by us and others [39, 40]. The aberrantly overexpressed YAP1 accumulates in the nuclei and binds with TEAD TF to activate the expression of CTGF and c-Myc. In this study, we provide the first evidence that YAP1 is regulated by the c-Jun TF, which functions as the well-known downstream of FGFR–FGFR–MAPK signaling in GC development [41]. The elucidation of novel mechanisms provides a potential for developing combinational therapeutic strategies.
To effectively targeting FGFR-related signaling, specific monoclonal antibodies and small-molecule inhibitors have been developed. The small molecules can be divided into non-selective and selective inhibitors. Among all the selective FGFR inhibitors, AZD4547 shows potent preclinical activity in gastric adenocarcinomas with FGFR2 amplification and other
The co-activation FGFR2–c-Jun–YAP1 axis correlates with unfavorable outcomes. a The genetic aberration and mRNA expression alterations of FGFR18, FGFR2, JUN, and YAP1 in the TCGA cohort. The changes between each gene were mutually exclusive (p < 0.001). b The expression correlation of FGFR2 and YAP1 in primary GC cases and diffuse type GC cases (TCGA cohort). c The correlation analysis of YAP1 and JUN in primary GC samples (TCGA cohort). In diffuse type GC cases, the positive correlation is more stringent (p < 0.001). d Representative IHC images of FGFR2–c-Jun–YAP1 co-positive and negative cases. The primary samples were stratified as two subgroups according to the expression of membrane/cyttoplasmic FGFR2, nuclear c-Jun, and nuclear YAP1 accumulation (scale bar, 20 μm). e GC cases with FGFR2–c-Jun–YAP1 co-activation were associated with poor disease-specific survival (p < 0.001). In diffuse type GC, the co-overexpression of these three biomarkers predicted more unfavorable com (p < 0.001).

Figure 6: The co-activation FGFR2–c-Jun–YAP1 axis correlates with unfavorable outcomes.

Materials and methods

GC cell lines and primary samples

The source of human GC cell lines and tissue microarray have been described previously [44]. Human sample usage was approved by the Joint Chinese University of Hong Kong—New Territories East Cluster Clinical Research Ethics Committee (CREC Ref. No.: 2019.406).

Chromogenic in situ hybridization (CISH)

FGFR2 probe (ZytoDot 2C SPEC FGFR2/CEN 10 Probe, C-3056; ZytoDot 2C CISH Implementation Kit, C-3044, Zytovision, Germany) was used to check the copy number gain and gene amplification in primary GC samples (Hong Kong cohort).

Quantitative real-time polymerase chain reaction (qRT-PCR)

Total RNA extraction and qRT-PCR have been described [44]. The primer sequences used in this study were listed in Supplementary Table S5.

Western blot analysis

Assays were performed as a previous study [44]. Antibodies were from Cell Signaling (Danvers, MA), including Phospho-FGFR (Tyr653/654) (#3471), Phospho-MEK1/2 (#9121), Phospho-p44/42 MAPK (#9106), p44/42 MAPK (#4695), Cyclin D1 (#2978), p21 (#2946), p27 (#2552), Phospho-Rb (Ser807/811) (#9308), cleaved PARP (Asp214) (#9541), PARP (#9542), LATS1 (#9153), LATS2 (#5888) Phospho c-Jun (Ser73) (#3270), c-Jun (#9165), c-Myc (#9402); Abcam (MA, US), including anti-FGFR2 (ab58201), and anti-YAP1 (ab52771); Immunoway (TX, US), including Bcl2 (YM3041) and β-Actin (YM3115); Santa Cruz (TX, US) including CTGF (sc-14939) and TEAD4 (TEF-3, sc-101184). The other antibodies include Phospho-LATS1/2 (Ser909/872) (AP0904, Abclonal), N-cadherin (#33-3900, ZYMED).

Immunohistochemistry (IHC) and immunofluorescence (IF)

IHC was conducted on the TMA and xenograft samples using Ventana NexES automated Stainer (Ventana Corporation). Primary antibodies for IF include YAP1 and α-Tubulin. Alexa Fluor 488 Phalloidin (Invitrogen) used as a F-actin indicator. Nuclei were counterstained with DAPI (Sigma-Aldrich). Images were acquired by confocal microscope Carl Zeiss LSM880 (Gottingen, Germany).

In vitro functional studies

GC cells were transfected with either QIAGEN FlexiTube siFGFR2 (SI02623047 and SI04948902), siJUN (SI00300580), or siScramble control (SI03650318). Detailed functional test procedures were previously described [44]. Recombinant human FGF18 (rhFGF18) (100-28, PeproTech) was employed to induce activation of FGFR.

RNA sequencing analysis

MGC-803 was used for screening the expression-altered genes after rhFGF18 stimulation or FGFR2 depletion. RNA-seq was performed by HiSeq-PE150 (Medikonia). Bioinformatics analysis revealed the alteration of biological processes by GO enrichment analysis [45]. Primer sequences for the validation of candidate genes were listed in Supplementary Table S5.
FGF18–FGFR2 signaling triggers the activation of c-Jun–YAP1 axis to...
Immunoprecipitation assays

For chromatin immunoprecipitation (ChIP), the promoter region of YAP1 was defined within 2000 base pairs upstream of the transcription start site and the sequence was obtained from the UCSC Table Browser [46]. Based on TRANSFAC (version 8.3), two putative binding sites of c-Jun were predicted at the region [47, 48]. Crosslinking, lysis, and chromatin shearing were performed as previously described [25]. Targeted fragments (300–500 base pairs) were pulled down by Magnetic Dynabeads Protein G (1004, Life Tech), with c-Jun antibody or Normal IgG antibody. Primers for binding site sequences are listed in Supplementary Table S5. For co-immunoprecipitation, 500 µg cell lysate was used for immunoprecipitation with 20 µl magnetic beads, bonding with YAP1 antibody or normal IgG antibody. A light chain-specific secondary antibody (ab99632, Abcam) were used to avoid the signal of the heavy chain (~50 kDa).

Drug sensitivity test

Cells were seeded (5000 cells/well). Varying doses of 5-Fluorouracil (5-FU: 0, 10, 20, 50, 100, 250 µg/ml) or AZD4547 (0, 0.1, 1, 2, 5, 10 µM) were added. After 48 h, cell viability was evaluated by using Cell Counting Kit, CCK-8 (Dojindo, Kumamoto, Japan). Data were recorded at 450 nm absorbance and proportioned to the number of living cells.

In vivo xenograft formation assay

MGC-803-derived xenografts was used for the efficacy appraisal of combinational administration. Total 20 mice were subcutaneously injected with 10^7 MGC-803 cells for each mouse. After 4 days’ inoculation, when the xenografts were palpable (~20 mm³), the mice were randomly divided as four groups (n = 5/group) and then treated with vehicle, AZD4547 (5 mg/kg/day by oral gavage), VP (20 mg/kg by intraperitoneal injection every other day), or the combination of AZD4547 and VP, respectively, for consecutive 24 days. Tumors size were measured every 4 days by digital calipers. The mice were sacrificed 28 days after the inoculation for immunostaining analysis. All the animal handling was approved by the Animal Experimentation Ethics Committee, The Chinese University of Hong Kong (Ref. No. 19-042-GRF).

Statistical analysis

All statistical analysis was performed using Graphpad Prism (version 8.0.1) and SPSS software (version 22.0; SPSS Inc). The student’s t test was used to compare the expression level of FGFR2 in the TCGA cohort, as well as the functional differences between siRNA-transfectants and controls. Cox regression was applied to indicate the survival rate for each parameter. For those variables that were found statistically significant in the univariate survival analysis, the Cox proportional hazards model with the likelihood ratio statistics was employed to assess them for multivariate survival analysis. The half-maximal inhibitory concentration (IC50) was calculated under a nonlinear regression model and statistical significance among treatment groups was determined by ANOVA. Two-tailed p values of <0.05 were deemed as statistically significant and those of <0.001 were highly statistically significant.

Acknowledgements We thank the TCGA Research Network (http://cancergenome.nih.gov/), The UCSC Cancer Genomics Browser (https://
All authors participated in data interpretation and approved the reviewed the manuscript and made thorough revisions on the drafts. WKKW, MWYC, ASLC, JY, NW, and KWL performed bioinformatics and statistical analysis. JZ and WK drafted conducted most of the experiments and analyzed the results. FW the study. JZ, CCW, KTL, YZ, JHMT, RCKC, YW, HY, HL, and LL conceived the idea and designed the study. JZ, CCW, KTL, YZ, JHMT, RCKC, YW, HY, HL, and LL conducted most of the experiments and analyzed the results. FW performed bioinformatics and statistical analysis. JZ and WK drafted the manuscript. WKKW, MWYC, ASLC, JY, NW, and KWL reviewed the manuscript and made thorough revisions on the drafts. All authors participated in data interpretation and approved the final version of the manuscript.

Author contributions WK and KFT conceived the idea and designed the study. JZ, CCW, KTL, YZ, JHMT, RCKC, YW, HY, HL, and LL conducted most of the experiments and analyzed the results. FW performed bioinformatics and statistical analysis. JZ and WK drafted the manuscript. WKKW, MWYC, ASLC, JY, NW, and KWL reviewed the manuscript and made thorough revisions on the drafts. All authors participated in data interpretation and approved the final version of the manuscript.

Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of interest.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
2. Bosetti C, Bertuccio P, Levi F, Lucchini F, Negri E, La, et al. Cancer mortality in the European Union, 1970-2003, with a joinpoint analysis. Ann Oncol. 2008;19:631–40.
3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
4. Leung WK, Wong IOL, Cheung KS, Yeung KF, Chan EW, Wong AYS, et al. Effects of helicobacter pylori treatment on incidence of gastric cancer in older individuals. Gastroenterology. 2018;155:67–75.
5. Hu B, El Hajj N, Sittler S, Lammert N, Barnes R, Meloni-Ehri A. Gastric cancer: classification, histology and application of molecular pathology. J Gastrointest Oncol. 2012;3:251–61.
6. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.
7. Yanai K, Nakamura M, Akiyoshi T, Nagai S, Wada J, Koga K, et al. Crosstalk of hedgehog and Wnt pathways in gastric cancer. Cancer Lett. 2008;263:145–56.
8. Katoh M, Katoh M. Cross-talk of WNT and FGF signaling pathways at GSK3beta to regulate beta-catenin and SNAIL signaling cascades. Cancer Biol Ther. 2006;5:1059–64.
9. Ohta H, Aoyagi K, Fukaya M, Danjoh I, Ohta A, Isohata N, et al. Cross talk between hedgehog and epithelial-mesenchymal transition pathways in gastric pit cells and in diffuse-type gastric cancers. Br J Cancer. 2009;100:389–98.
10. Zhang J, Zhou Y, Huang T, Wu F, Pan Y, Dong Y, et al. FGFR18, a prominent player in FGF signaling, promotes gastric tumorigenesis through autocrine manner and is negatively regulated by miR-590-5p. Oncogene. 2019;38:33–46.
11. Katoh M. FGF signaling network in the gastrointestinal tract. Int J Oncol. 2006;29:163–8.
12. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005;16:139–49.
13. Thissie B, Thissie C. Functions and regulations of fibroblast growth factor signaling during embryonic development. Dev Biol. 2005;287:390–402.
14. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10:116–29.
15. Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res. 2012;18:1855–62.
16. Turner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R, et al. Integrative molecular profiling of triple negative breast cancers identifies ampiclon drivers and potential therapeutic targets. Oncogene. 2010;29:2013–23.
17. Liao RG, Jung T, Tchaicha J, Willkerson MD, Sivachenko A, Beauchamp EM, et al. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res. 2013;73:5195–205.
18. Su X, Zhan P, Gavine PR, Morgan S, Womack C, Ni X, et al. FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study. Br J Cancer. 2014;110:967–75.
19. Matsuda Y, Hagio M, Seya T, Ishiwata T. Fibroblast growth factor receptor 2 IIIC as a therapeutic target for colorectal cancer cells. Mol Cancer Ther. 2012;11:2010–20.
20. Zhang C, Fu L, Fu J, Hu L, Yang H, Kong TH, et al. Fibroblast growth factor receptor 2-positive fibroblasts provide a suitable microenvironment for tumor development and progression in esophageal carcinoma. Clin Cancer Res. 2009;15:4017–27.
21. Ahn S, Lee J, Hong M, Kim ST, Park SH, Choi MG, et al. FGFR2 amplification of triple negative breast cancers identifies ampiclon drivers and potential therapeutic targets. Oncogene. 2010;29:2013–23.
22. Matsuda Y, Hagio M, Seya T, Ishiwata T. Fibroblast growth factor receptor 2 IIIC as a therapeutic target for colorectal cancer cells. Mol Cancer Ther. 2012;11:2010–20.
23. Zhang C, Fu L, Fu J, Hu L, Yang H, Kong TH, et al. Fibroblast growth factor receptor 2-positive fibroblasts provide a suitable microenvironment for tumor development and progression in esophageal carcinoma. Clin Cancer Res. 2009;15:4017–27.
24. Ahn S, Lee J, Hong M, Kim ST, Park SH, Choi MG, et al. FGFR2 amplification of triple negative breast cancers identifies ampiclon drivers and potential therapeutic targets. Oncogene. 2010;29:2013–23.
25. Zhang W, Huang T, Zhou Y, Cheng ASL, Yu J, Kang W, et al. Targeting the oncogenic FGF-FGFR axis in gastric carcinogenesis. Cell Death Dis. 2018;9:92.
26. Zhang J, Zhou Y, Tang PMK, Cheng ASL, Yu J, To KF, et al. Mechanotransduction and cytoskeleton remodeling shaping YAP1 in gastric tumorigenesis. Int J Mol Sci. 2019:20:1576.

27. Fornes O, Castro-Mondragon JA, Khan A, van der Lee R, Zhang X, Richmond PA, et al. JASPAR 2020: update of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2020;48:D887–92.

28. Haugsten EM, Wiedlocha A, Olness S, Wesche J. Roles of fibroblast growth factor receptors in carcinogenesis. Mol Cancer Res. 2010;8:1439–52.

29. Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clin Cancer Res. 2016;22:259–67.

30. Dienstmann R, Rodon J, Prat A, Perez-Garcia J, Adamo B, Felip E, et al. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann Oncol. 2014;25:552–63.

31. Chang J, Wang S, Zhang Z, Liu X, Wu Z, Geng R, et al. Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer. Oncotarget. 2015;6:2099–20.

32. Tsang M, Dawid IB. Promotion and attenuation of FGF signaling through the Ras-MAPK pathway. Sci STKE. 2004;2004:pe17.

33. Dey JH, Bianchi F, Voshol J, Bonenfant D, Oakeley EJ, Hynes NE. Targeting fibroblast growth factor receptor blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res. 2010;70:4151–62.

34. Peters KG, Marie J, Wilson E, Oakeley EJ, Hynes NE. Point mutation of an FGFR receptor abolishes phosphorylation of GSK3beta. Mol Cancer Ther. 2018;17:232–42.

35. Dudka AA, Sweet SM, Heath JK. Signal transducers and activators of transcription-3 binding to the fibroblast growth factor receptor is activated by receptor amplification. Cancer Res. 2010;70:3391–401.

36. Lau WM, Teng E, Huang KK, Tan JW, Das K, Zang Z, et al. Acquired resistance to FGFR inhibitor in diffuse-type gastric cancer through an AKT-independent PKC-mediated phosphorylation of GSK3beta. Mol Cancer Ther. 2018;17:232–42.

37. Shoji H, Yamada Y, Okita N, Takashima A, Homma Y, Iwasa S, et al. Amplification of FGFR2 gene in patients with advanced gastric cancer receiving chemotherapy: prevalence and prognostic significance. Anticancer Res. 2015;35:5055–61.

38. Kim HS, Kim JH, Jang HJ, Han B, Zang DY. Pathological and prognostic impacts of FGFR2 overexpression in gastric cancer: a meta-analysis. J Cancer. 2019:10:20–7.

39. Kang W, Tong JH, Chan AW, Lee TL, Lung RW, Leung PP, et al. Yes-associated protein 1 exhibits oncosgenic property in gastric cancer and its nuclear accumulation associates with poor prognosis. Clin Cancer Res. 2011;17:2130–9.

40. Sun D, Li X, He Y, Li W, Wang Y, Wang H, et al. YAP1 enhances cell proliferation, migration, and invasion of gastric cancer in vitro and in vivo. Oncotarget. 2016;7:81062–76.

41. Mitsuno Y, Yoshida H, Maeda S, Ogura K, Hirata Y, Kawabe T, et al. Helicobacter pylori induced transactivation of SRE and AP-1 through the ERK signaling pathway in gastric cancer cells. Gut. 2001;49:18–22.

42. Xie L, Su X, Zhang L, Yin X, Tang L, Zhang X, et al. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin Cancer Res. 2013;19:2572–83.

43. Jang J, Kim HK, Bang H, Kim ST, Kim SY, Park SH, et al. Antitumor effect of AZD4547 in a fibroblast growth factor receptor 2-amplified gastric cancer patient-derived cell model. Transl Oncol. 2017;10:469–75.

44. Huang T, Kang W, Zhang B, Wu F, Dong Y, Tong JH, et al. miR-508-3p concordantly silences NFKB1 and RELA to inactivate canonical NF-kappaB signaling in gastric carcinogenesis. Mol Cancer. 2016;15:9.

45. Mi H, Muruganujan A, Ebert D, Huang X, Thomas PD. PANTHER version 14: more genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools. Nucleic Acids Res. 2019;47:D419–26.

46. Karolchik D, Hinrichs AS, Furey TS, Roskin KM, Sugnet CW, Haussler D, et al. The UCSC table browser data retrieval tool. Nucleic Acids Res. 2004:32:D493–96.

47. Messeguer X, Escudero R, Farre D, Nunez O, Martinez J, Alba MM. PROMO: detection of known transcription regulatory elements using species-tailored searches. Bioinformatics. 2002;18:333–4.

48. Farre D, Roset R, Huerta M, Aduaera JE, Rosello L, Alba MM, et al. Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. Nucleic Acids Res. 2003;31:3651–3.

Affiliations

Jinglin Zhang1,2,3 · Chi Chun Wong2 · Kam Tong Leung4 · Feng Wu1 · Yuhang Zhou1,2,3 · Joanna H. M. Tong1,2,3 · Ronald C. K. Chan1 · Hui Li1,2,3 · Yifei Wang1,2,3 · Huan Yan1,2,3 · Liping Liu5 · William K. K. Wu6 · Michael W. Y. Chan7 · Alfred S. L. Cheng8 · Jun Yu2,9 · Nathalie Wong9,10 · Kwok Wai Lo1,3 · Ka Fai To1,2,3 · Wei Kang1,2,3

1 Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, PR China

2 Institute of Digestive Disease, State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, PR China

3 Li Ka Shing Institute of Health Science, Sir Y.K. Pao Cancer Center, The Chinese University of Hong Kong, Hong Kong SAR, PR China

4 Department of Pediatrics, The Chinese University of Hong Kong, Hong Kong SAR, PR China

5 Center, The Chinese University of Hong Kong, Hong Kong SAR, PR China
FGF18–FGFR2 signaling triggers the activation of c-Jun–YAP1 axis to...